Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,163.00-0.95%ETH$2,458.75+0.41%GOLD$4,363.20-1.00%OIL$103.90+1.39%
Smart Investors Daily
Avalo Therapeutics, Inc. logo

NASDAQ · AVTX

Avalo Therapeutics, Inc.

Healthcare · Biotechnology

$18.21

Down-$1.03 (-5.66%)

Updated Sep 10, 2026, 9:30 PM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
220.35M
P/E ratio
-2.73
Dividend yield
0.00%
52-week range
$12.51 – $24.27
Volume
725.72K
Avg. volume
410.27K

Price performance

AVTX price history

1M range · 20 trading sessions · Daily adjusted prices

AVTX closed at $18.21 after 20 trading sessions, down 6.85% for the selected period.

Last close
$18.21
Period change
-6.85%
Period low
$18.21
Period high
$20.75
Daily close
View OHLC price history
AVTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$19.47$19.74$18.035$18.21725.72K
Sep 8, 2026$19.01$20.49$18.95$19.71779.7K
Sep 4, 2026$18.81$19.62$18.79$19.23633.23K
Sep 3, 2026$19.57$19.57$18.73$19.00674.04K
Sep 2, 2026$19.00$19.855$19.00$19.34988.02K
Sep 1, 2026$19.19$19.70$18.85$18.95606.64K
Aug 31, 2026$19.40$19.58$19.00$19.341.38M
Aug 28, 2026$19.87$20.175$19.54$19.59738.28K
Aug 27, 2026$20.47$20.568$19.91$20.05420.54K
Aug 26, 2026$19.74$20.94$19.61$20.55813.99K
Aug 25, 2026$19.54$20.05$19.36$19.741.02M
Aug 24, 2026$19.86$19.86$18.88$19.27759.04K
Aug 21, 2026$20.02$20.19$19.58$19.83569.83K
Aug 20, 2026$20.38$20.59$19.49$19.82698.46K
Aug 19, 2026$20.41$21.02$20.14$20.75999.05K
Aug 18, 2026$19.91$20.46$19.62$19.711.07M
Aug 17, 2026$19.48$20.07$19.325$19.95646.97K
Aug 14, 2026$19.13$19.63$18.34$19.59388.07K
Aug 13, 2026$19.65$19.67$19.19$19.45391.15K
Aug 12, 2026$19.52$19.77$19.27$19.55317.25K

Latest AVTX news

The latest Smart Investors Daily articles mentioning AVTX.

Stock researchCompany · Overview

AVTX research

Overview

Company profile and research snapshot.

Company profile

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$25.00
Implied upside
—
Analysts
—
AVTX recent ratings
DateFirmRatingTarget
Aug 7, 2026GuggenheimBuy—
Aug 7, 2026HC Wainwright & Co.Buy—
Jul 6, 2026Leerink PartnersOutperform—
Jun 16, 2026BTIGBuy—
Jun 12, 2026B of A SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as

Yahoo · Sep 3, 2026

Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare Conference 2026 Fireside ChatSeptember 10, 2026, at 8:00 am ET Morgan Stanley 24th Annual Global Healthcare Conference 1x1 meetings onlySeptember 16, 20

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By